Deka Bank Deutsche Girozentrale Intercept Pharmaceuticals, Inc. Transaction History

Deka Bank Deutsche Girozentrale

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 02, 2022	SELL	$14.28 - $19.53 $158,365 - $216,587	-11,090 Closed	0 $0
Q3 2020 Oct 29, 2020	BUY	$39.09 - $53.44 $433,508 - $592,649	11,090 New	11,090 $457,000
Q4 2019 Feb 04, 2020	SELL	$57.36 - $124.1 $816,806 - $1.77 Million	-14,240 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$58.69 - $80.46 $888,566 - $1.22 Million	-15,140 Reduced 51.53%	14,240 $913,000
Q2 2019 Aug 01, 2019	BUY	$77.77 - $120.68 $1.66 Million - $2.58 Million	21,390 Added 267.71%	29,380 $2.33 Million
Q1 2019 May 10, 2019	SELL	$91.83 - $120.68 $615,261 - $808,556	-6,700 Reduced 45.61%	7,990 $878,000
Q4 2018 Feb 12, 2019	BUY	$85.79 - $126.46 $574,793 - $847,282	6,700 Added 83.85%	14,690 $1.37 Million
Q3 2018 Nov 09, 2018	SELL	$88.49 - $127.55 $17,698 - $25,510	-200 Reduced 2.44%	7,990 $0
Q1 2018 May 03, 2018	SELL	$52.72 - $67.25 $10,544 - $13,450	-200 Reduced 2.38%	8,190 $493,000
Q3 2017 Nov 06, 2017	BUY	$57.01 - $118.75 $478,313 - $996,312	8,390	8,390 $885,000

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.